UBS Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $27
UBS analyst Alice Nettleton initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $27.
Stocks · News reference
Odyssey Therapeutics Announces Presentation Of Additional Phase 2a OD-001 Ulcerative Colitis Data At UEG Week On October 20
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Odyssey Therapeutics To Present Design Of Randomized, Double-Blind Phase 2a Trial Evaluating OD-001 In Combination With Vedolizumab In Patients With UC At ACG 2026 Annual Scientific Meeting
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and
Odyssey Therapeutics shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and announced a $42 price target.
Raymond James Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $42